CXCR2 and neoplasm: There, an upregulation of IL8 and CXCR2 was demonstrated within the tumor after anti-angiogenic treatment with VEGF-pathway inhibitors and a decrease of tumor-derived endothelial-like cells as well as tumor stem cells after application of the CXCR2-antagoist SB225002 [18].